Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745052 | 0.75 | CHRNA7 (0.44) | CHRNA7KCNH2PARP1 | |
| SCHEMBL23123138 | 0.75 | CHRNA7 (0.44) | CHRNA7KCNH2PARP1 | |
| SCHEMBL23122838 | 0.75 | CHRNA7 (0.44) | CHRNA7KCNH2PARP1 | |
| SCHEMBL23123423 | 0.75 | CHRNA7 (0.44) | CHRNA7KCNH2PARP1 | |
| SCHEMBL15790567 | 0.72 | CHRNA7 (0.51) | CHRNA7KCNH2PARP1 | |
| SCHEMBL19381894 | 0.72 | CHRNA7 (0.58) | CHRNA7KCNH2PARP1 | |
| SCHEMBL26235665 | 0.72 | CHRNA7 (0.58) | CHRNA7KCNH2PARP1 | |
| SCHEMBL3413859 | 0.71 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL30912434 | 0.71 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL30912529 | 0.71 | MAPT (0.45) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | CHRNA7 3236/4885KCNH2 2163/4885PARP1 4586/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | CHRNA7 3465/4885KCNH2 1884/4885PARP1 4518/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | CHRNA7 1782/4885KCNH2 1222/4885PARP1 3718/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | CHRNA7 3465/4885KCNH2 1884/4885PARP1 4518/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | CHRNA7 3236/4885KCNH2 2163/4885PARP1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.